Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled add-on AMG 747 in schizophrenia negative symptoms (Study 165)
2011-004845-42Phase 2Terminated
- Sponsor
- Amgen
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing AMG 747 add-on with Placebo add-on (2 arms). Primary endpoint: Change in NSA-16 total score at week 12. Started Mar 2012; status: terminated.
02
Drugs
tilapertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2011-004845-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004845-42.